XML 45 R5.htm IDEA: XBRL DOCUMENT v3.3.0.814
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Cash flows from operating activities:    
Net loss $ (15,981,000) $ (31,612,000)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 761,000 525,000
Amortization of deferred financing costs and debt discount 714,000 961,000
Joint Venture acquisition obligation accretion 340,000 362,000
Provision for doubtful accounts 0 1,126,000
Provision for expired enzyme 0 313,000
Change in fair value of warrants (4,988,000) (134,000)
Stock-based compensation expense 1,617,000 2,566,000
Loss on asset disposal 5,000 15,000
Loss on debt extinguishment 260,000 0
Increases (decreases) in cash caused by changes in operating assets and liabilities:    
Accounts receivable 131,000 2,505,000
Inventories (10,000) (1,158,000)
Other current assets (258,000) (19,000)
Other assets 762,000 (124,000)
Accounts payable and accrued expenses 870,000 (666,000)
Deferred revenues 41,000 47,000
Long-term deferred rent (210,000) (81,000)
Net cash used in operating activities (15,946,000) (25,374,000)
Cash flows from investing activities:    
Purchases of property and equipment (544,000) (792,000)
Expenditures for intellectual property (13,000) (255,000)
License agreement termination fee 0 (400,000)
Net cash used in investing activities (557,000) (1,447,000)
Cash flows from financing activities:    
Principal payments on long-term obligations (25,032,000) (1,303,000)
Proceeds from long-term obligations 17,700,000 0
Debt issuance costs and loan fees (1,854,000) 0
Joint Venture purchase payments (1,623,000) (2,236,000)
Proceeds from exercise of employee stock options and warrants 4,986,000 4,066,000
Proceeds from sale of common stock, net 26,749,000 18,650,000
Dividends paid on preferred stock (75,000) 0
Net cash provided by financing activities 20,851,000 19,177,000
Effect of exchange rate changes on cash and cash equivalents 0 (13,000)
Net increase (decrease) in cash and cash equivalents 4,348,000 (7,657,000)
Cash and cash equivalents at beginning of period 14,622,000 15,506,000
Cash and cash equivalents at end of period 18,970,000 7,849,000
Cash paid during period for:    
Interest 1,607,000 1,972,000
Supplemental schedule of non-cash investing and financing activities:    
Fair value of warrants allocated to (from) additional paid-in capital 0 (296,000)
Conversion of preferred stock into common stock 10,000 0
Declared dividend related to preferred stock $ 3,000 $ 0